Medicamen Biotech Limited

MEDICAMEQ

INE646B01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:54 2024-07-15 am EDT			5-day change	1st Jan Change
483.2 ^INR	-1.35%		+1.29%	-19.79%

May. 31	Medicamen Biotech Receives Observations from Greek Regulatory Body; Shares Up 4%	MT
May. 29	Medicamen Biotech Limited Recommends Final Dividend for the Year 2023-24	CI

Medicamen Biotech Ltd. Takes Decision on Change of Registered Office

January 06, 2016 at 02:00 am EST

Medicamen Biotech Ltd. has informed that the Board of Directors of the company at its meeting held on January 04, 2016, has taken decision on change of registered office of the company from '10, Community Centre No. 2, Ashok Vihar, Phase -II Delhi-110052' to '1506, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019'.

Latest news about Medicamen Biotech Limited

Medicamen Biotech Receives Observations from Greek Regulatory Body; Shares Up 4%	May. 31	MT
Medicamen Biotech Limited Recommends Final Dividend for the Year 2023-24	May. 29	CI
Medicamen Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 29	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 29	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
Medicamen Biotech Limited Recommends Final Dividend for Financial Year 2022-23	23-05-29	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI
INDIA STOCKS-Indian shares seen opening higher as global equities attempt bounce	22-10-03	RE
Medicamen Biotech Forays into Domestic Indian Pharmaceutical Business	22-10-03	MT
Medicamen Biotech Forms New Unit	22-08-26	MT
Medicamen Biotech Ties Up with Danish Pharmaceutical Firm for Manufacturing of Drugs	22-08-12	MT
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-10	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-25	CI
Medicamen Biotech Limited Recommends Final Dividend for the Financial Year 2021-22	22-05-25	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-08	CI
Promoter Group Narrows Stake in Medicamen Biotech	22-01-03	MT
Promoter Group Lowers Stake in Medicamen Biotech to 2.93%	21-12-10	MT
Medicamen Biotech's Consolidated Net Profit Climbs in Fiscal Q2	21-11-05	MT
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-03	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-13	CI
Medicamen Biotech Limited Recommends Final Dividend for the Fiscal Year 2021	21-06-26	CI

Chart Medicamen Biotech Limited

Duration

Period

More charts

Company Profile

Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. It focuses on oncology therapeutics, and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company primarily focuses on oncology therapeutics. It is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICAMEN BIOTECH LIMITED	-19.79%	74.57M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.94%	45.32B
OTSUKA HOLDINGS CO., LTD.	+35.05%	24.51B
SANDOZ GROUP AG	+26.79%	16.85B
CIPLA LIMITED	+21.74%	14.62B
ZYDUS LIFESCIENCES LIMITED	+72.37%	14.16B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.63%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+18.15%	5.82B
STADA ARZNEIMITTEL	-8.87%	5.73B